This page compares ibogaine and ketamine therapy across the criteria that matter most — mechanism of action, clinical evidence, safety profile, cost, legal access, and patient fit. Both are psychoactive treatments being studied for addiction and mental health, but they differ substantially in nearly every dimension.

At a Glance

Criterion Ibogaine Ketamine Therapy
Primary Mechanism Multi-target: NMDA antagonism, opioid receptor modulation, serotonin reuptake inhibition, sigma-2 receptor activity NMDA receptor antagonism, AMPA receptor potentiation, rapid BDNF release
Evidence Level Phase 1–2 trials, observational studies, case series; Phase 2 RCTs underway Multiple RCTs; FDA-approved esketamine (Spravato) for treatment-resistant depression
Session Duration 24–36 hours (single session often sufficient) 45–60 minutes per infusion; typically 6 infusions over 2–3 weeks
Legal Status (US) Schedule I — no approved medical use federally; legal in some countries Ketamine: legal for off-label use; esketamine (Spravato): FDA-approved
Access Licensed clinics in Mexico, Canada, Portugal, Netherlands, and others Widely available at US clinics; Spravato in certified healthcare settings
Typical Cost $5,000–$12,000+ per treatment retreat $400–$800 per IV infusion; $6 sessions ≈ $2,400–$4,800
Key Risks QTc prolongation, cardiac arrhythmia, fatality risk; contraindicated with many medications Dissociation, blood pressure elevation, potential for misuse; generally well-tolerated
Best Studied For Opioid use disorder, alcohol use disorder, PTSD Treatment-resistant depression, suicidal ideation, chronic pain

Mechanism of Action

Understanding how each treatment works helps explain both their effects and their risks.

Ibogaine

Ibogaine is an indole alkaloid derived from the Tabernanthe iboga shrub. Its pharmacology is unusually complex. It acts as a non-competitive NMDA receptor antagonist, an agonist and antagonist at multiple opioid receptor subtypes, a serotonin reuptake inhibitor, and a sigma-2 receptor agonist. Its active metabolite noribogaine has a significantly longer half-life (up to 48 hours) and is believed to sustain many of ibogaine's therapeutic effects, particularly its interaction with opioid receptors. This multi-receptor profile is hypothesized to explain its reported ability to dramatically reduce opioid withdrawal symptoms and craving in a single session — an effect not seen with other treatments.

Ketamine

Ketamine primarily works by blocking NMDA receptors, which interrupts glutamatergic transmission. This triggers a rapid downstream release of brain-derived neurotrophic factor (BDNF) and activation of mTOR signaling pathways, promoting synaptic plasticity. Unlike classic antidepressants that take weeks to act, ketamine's antidepressant effects can appear within hours of a single infusion. Esketamine (the S-enantiomer of ketamine) has a more selective receptor profile and is the basis of the FDA-approved nasal spray Spravato. Both share the dissociative, anesthetic quality that makes set and setting important during sessions.

Clinical Evidence

Ibogaine

Ibogaine's evidence base is growing but remains behind ketamine's in rigor and volume. Observational studies and case series from clinics in Mexico, Canada, and Europe have consistently reported significant reductions in opioid withdrawal symptoms and cravings following a single treatment. A landmark 2023 Stanford study published in Nature Medicine found that ibogaine combined with magnesium dramatically reduced PTSD, depression, and anxiety symptoms in veterans, with effects sustained at one-month follow-up. Phase 2 randomized controlled trials for opioid use disorder are currently enrolling or in progress. The evidence is promising but not yet at the level required for regulatory approval in the US or EU.

Ketamine

Ketamine has a substantially larger and more rigorous evidence base. Dozens of RCTs have examined IV ketamine for treatment-resistant depression (TRD), and the results are consistently positive for rapid symptom reduction. The 2019 FDA approval of intranasal esketamine (Spravato) for TRD and major depressive disorder with acute suicidal ideation marked a regulatory milestone. Evidence for ketamine in PTSD, OCD, and alcohol use disorder is accumulating, though these remain off-label. The primary limitation is durability — antidepressant effects typically last days to weeks, often necessitating repeated treatment series or maintenance infusions.

Safety and Risks

⚠️ Ibogaine carries serious cardiac risks and has caused fatalities. Medical supervision and pre-treatment cardiac screening required.

Ibogaine

Ibogaine's safety profile is the most significant barrier to its broader adoption. It prolongs the cardiac QTc interval, which can trigger life-threatening ventricular arrhythmias including torsades de pointes. Fatalities have been reported, most often in patients with undetected cardiac abnormalities or those who were not adequately screened for drug interactions. Rigorous pre-treatment protocols — including 12-lead ECG, liver function tests, full medication washout periods, and magnesium supplementation — substantially reduce but do not eliminate risk. Ibogaine is contraindicated in individuals with a history of cardiac disease, certain psychiatric diagnoses, and those taking a wide range of medications including SSRIs, antiarrhythmics, and opioids at the time of administration. The treatment also produces a prolonged and intense psychedelic experience that can be physically and psychologically demanding.

Ketamine

Ketamine has a well-established safety record from decades of use as a surgical anesthetic. In sub-anesthetic therapeutic doses, serious adverse events are uncommon. The most frequently reported side effects are transient dissociation, dizziness, nausea, and blood pressure elevation during infusion. Long-term or high-frequency use carries a risk of ketamine cystitis (bladder damage) and psychological dependence, but these are rarely observed at the doses and frequencies used in clinical treatment protocols. Patients with a history of psychosis or uncontrolled hypertension require additional screening. The requirement for monitored administration (IV infusion or supervised nasal spray) and the relatively short duration of effect reduce many practical risks.

Cost and Access

Ibogaine

Ibogaine is not legally available in the United States, where it remains a Schedule I substance. Patients seeking treatment typically travel to licensed clinics in Mexico, Canada (where some exemptions exist), Portugal, the Netherlands, or other jurisdictions where it is legal or decriminalized. All-inclusive retreat packages — which typically include pre-screening, the session itself, medical monitoring, integration support, and accommodations — generally range from $5,000 to $12,000 or more. Travel and time off work add to the total cost. Insurance does not cover ibogaine treatment. Access is therefore limited to those with financial means and the ability to travel internationally, creating a significant equity gap.

Ketamine

Ketamine therapy is broadly accessible in the United States and many other countries. Hundreds of standalone ketamine clinics operate across the US, and IV ketamine is legally administered off-label for depression and other conditions. FDA-approved esketamine (Spravato) is available through certified healthcare providers and is covered by some insurance plans for qualifying diagnoses. A standard induction course of six IV infusions typically costs between $2,400 and $4,800 out of pocket, with individual infusion prices varying by region and clinic. Telehealth-connected ketamine services have also expanded access, though these models typically use oral or sublingual ketamine lozenges rather than IV infusion, which may have a different efficacy profile.

Who Each Treatment May Suit

Ibogaine may be considered by individuals who:

  • Are seeking treatment for opioid use disorder and have not responded to or do not wish to use methadone or buprenorphine
  • Have alcohol use disorder or stimulant use disorder with limited response to existing treatments
  • Are dealing with treatment-resistant PTSD, particularly in combination with substance use
  • Have no contraindicated cardiac conditions and are willing to undergo thorough pre-treatment medical screening
  • Can access and afford treatment at an international clinic and engage in post-treatment integration support

Ketamine therapy may be considered by individuals who:

  • Have been diagnosed with treatment-resistant depression or major depressive disorder with suicidal ideation
  • Need rapid symptom relief where weeks-long delays from standard antidepressants are not acceptable
  • Are dealing with chronic pain conditions that have not responded to conventional management
  • Prefer a legally accessible, clinic-based treatment with established protocols and insurance coverage potential
  • Are comfortable with repeated treatment sessions and ongoing maintenance as needed

Key Difference

Ibogaine and ketamine are both psychoactive treatments attracting serious clinical research attention, but they occupy different positions on nearly every relevant axis. Ketamine is legally available, supported by RCT evidence and an FDA approval, carries a well-characterized safety profile, and is most studied for depression — while its effects typically require repeated sessions to sustain. Ibogaine operates through a broader pharmacological mechanism, is most studied for substance use disorders, and is reported to produce meaningful clinical change in a single extended session; however, it carries substantially higher cardiac risk, is not legally available in the US, requires international travel for most patients, and has a smaller body of controlled trial evidence. The treatments are rarely in direct competition — their primary indications differ — but for patients considering either for overlapping conditions such as PTSD or alcohol use disorder, these distinctions in risk, access, evidence, and mechanism are the essential factors to weigh with qualified medical guidance.

Frequently Asked Questions

Sequential use is sometimes explored in clinical settings, particularly ibogaine followed by ketamine-assisted therapy as part of an integration protocol for trauma or addiction. However, combining or closely spacing these treatments carries unknown pharmacological risks and should only be considered under direct medical supervision. There is currently no published evidence base specifically examining combined protocols.
Ibogaine has a more developed evidence base specifically for opioid use disorder, with multiple observational studies and emerging RCT data showing significant reductions in withdrawal symptoms and cravings. Ketamine has limited evidence for opioid addiction specifically, though some research suggests it may reduce cravings and depression comorbid with opioid use. Neither is FDA-approved for opioid use disorder; buprenorphine and methadone remain the first-line evidence-based treatments.
Ketamine has a significantly better-characterized and generally safer short-term risk profile. It has been used as an anesthetic for decades, and serious adverse events at therapeutic doses are uncommon. Ibogaine carries a documented risk of fatal cardiac arrhythmia, particularly in patients with undetected cardiac conditions or those with certain drug interactions. With rigorous pre-treatment cardiac screening, ibogaine's risk can be substantially reduced, but it cannot be eliminated entirely. For patients with any cardiac history, ketamine is the substantially lower-risk option.
Ibogaine's acute effects last 24–36 hours, with its metabolite noribogaine remaining active for up to 48 hours or more. Many patients report sustained reductions in cravings and mood improvements for weeks to months after a single session, though outcomes vary and long-term follow-up data is limited. Ketamine's antidepressant effects typically last one to three weeks after an infusion course. Many patients require periodic maintenance infusions to sustain benefit. The durability gap is one reason ibogaine attracts particular interest for addiction treatment.
Esketamine (Spravato) administered in a certified provider's office is covered by many insurance plans for qualifying diagnoses such as treatment-resistant depression. IV ketamine infusions, which are administered off-label, are generally not covered by insurance and are an out-of-pocket expense. Coverage varies significantly by insurer and plan. Ibogaine treatment is not covered by any US insurance due to its Schedule I status.
Neither strictly requires psychotherapy, but clinical evidence and practitioner consensus strongly support combining both with preparation and integration work. Ketamine-assisted psychotherapy (KAP) formally structures therapy sessions around the ketamine experience and is associated with better outcomes than infusions alone in some research. Ibogaine retreats typically include some pre- and post-session integration support, and many providers recommend continued psychotherapy after the experience to consolidate insights and support behavioral change.
Currently, ibogaine remains a Schedule I controlled substance federally in the United States. However, regulatory momentum has been building. The FDA granted ibogaine Breakthrough Therapy designation for opioid use disorder in 2024, which is designed to expedite development and review of treatments addressing serious conditions. Several states have introduced decriminalization or research-enabling legislation. Full federal legalization would require successful Phase 3 trial data and FDA approval, a process that typically takes several years.
For depression as a primary diagnosis, ketamine has a substantially stronger and more current evidence base, including an FDA-approved formulation. Multiple RCTs have demonstrated rapid, meaningful reductions in depressive symptoms. Ibogaine has shown antidepressant effects in observational studies and in the 2023 Stanford veteran trial, but it has not been evaluated in large RCTs specifically for major depressive disorder. For depression without a co-occurring substance use disorder, ketamine is currently the better-supported option of the two.

Informational only. Not medical or legal advice. Ibogaine is Schedule I in the US. Consult qualified professionals before considering treatment.